These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21612232)

  • 1. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
    Nishimura N; Siegmund A; Liu L; Yang K; Bryan MC; Andrews KL; Bo Y; Booker SK; Caenepeel S; Freeman D; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Whittington DA; Zalameda L; Zhang N; Hughes PE; Norman MH
    J Med Chem; 2011 Jul; 54(13):4735-51. PubMed ID: 21612232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
    Herrera VA; Zeindl-Eberhart E; Jung A; Huber RM; Bergner A
    Anticancer Res; 2011 Mar; 31(3):849-54. PubMed ID: 21498705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
    Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
    J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.
    Peterson EA; Andrews PS; Be X; Boezio AA; Bush TL; Cheng AC; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Harmange JC; Kim JL; Mullady EL; Olivieri P; Schenkel LB; Stanton MK; Teffera Y; Whittington DA; Cai T; La DS
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2064-70. PubMed ID: 21376583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
    Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
    Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
    Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
    Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
    Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
    Takeuchi CS; Kim BG; Blazey CM; Ma S; Johnson HW; Anand NK; Arcalas A; Baik TG; Buhr CA; Cannoy J; Epshteyn S; Joshi A; Lara K; Lee MS; Wang L; Leahy JW; Nuss JM; Aay N; Aoyama R; Foster P; Lee J; Lehoux I; Munagala N; Plonowski A; Rajan S; Woolfrey J; Yamaguchi K; Lamb P; Miller N
    J Med Chem; 2013 Mar; 56(6):2218-34. PubMed ID: 23394126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
    Norman MH; Andrews KL; Bo YY; Booker SK; Caenepeel S; Cee VJ; D'Angelo ND; Freeman DJ; Herberich BJ; Hong FT; Jackson CL; Jiang J; Lanman BA; Liu L; McCarter JD; Mullady EL; Nishimura N; Pettus LH; Reed AB; Miguel TS; Smith AL; Stec MM; Tadesse S; Tasker A; Aidasani D; Zhu X; Subramanian R; Tamayo NA; Wang L; Whittington DA; Wu B; Wu T; Wurz RP; Yang K; Zalameda L; Zhang N; Hughes PE
    J Med Chem; 2012 Sep; 55(17):7796-816. PubMed ID: 22897589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
    Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
    J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
    Han F; Lin S; Liu P; Tao J; Yi C; Xu H
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4538-4541. PubMed ID: 25139570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
    Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
    Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
    J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.